Relonchem Limited receives Marketing Authorization for two of its products

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited in UK has received Marketing Authorization for the below-mentioned products from UK MHRA:

1. Clonidine 100 microgram Tablets
2. Clonidine Hydrochloride 25 microgram Tablets

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 180.85 as compared to the previous close of Rs. 177.85. The total number of shares traded during the day was 90386 in over 1543 trades.

The stock hit an intraday high of Rs. 182.70 and intraday low of 174.15. The net turnover during the day was Rs. 16184983.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Pharmaceuticals Relonchem UKMHRA Approval MarketingAuthorization Clonidine ClonidineHydrochloride